<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>54</viewCount><searchCount>0</searchCount></scores><additional><submitter>Halemano K</submitter><funding>NIAID NIH HHS</funding><pagination>7759-64</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4040588</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>111(21)</volume><pubmed_abstract>Somatic hypermutation (SHM) is an integral process in the development of high-affinity antibodies that are important for recovery from viral infections and vaccine-induced protection. Ig SHM occurs predominantly in germinal centers (GC) via the enzymatic activity of activation-induced deaminase (AID). In contrast, the evolutionarily related apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3 (APOBEC3) proteins are known to restrict retroviruses, including HIV-1. We previously reported that mouse APOBEC3 encodes Recovery from Friend virus 3 (Rfv3), a classical resistance gene in mice that promotes the neutralizing antibody response against retrovirus infection. We now show that APOBEC3/Rfv3 complements AID in driving Ig SHM during retrovirus infection. Analysis of antibody sequences from retrovirus-specific hybridomas and GC B cells from infected mice revealed Ig heavy-chain V genes with significantly increased C-to-T and G-to-A transitions in wild-type as compared with APOBEC3-defective mice. The context of the mutations was consistent with APOBEC3 but not AID mutational activity. These findings help explain the role of APOBEC3/Rfv3 in promoting the neutralizing antibody responses essential for recovery from retroviral infection and highlight APOBEC3-mediated deamination as a previously unidentified mechanism for antibody diversification in vivo.</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.</pubmed_title><pmcid>PMC4040588</pmcid><funding_grant_id>P30 AI027763</funding_grant_id><funding_grant_id>R01 AI116603</funding_grant_id><funding_grant_id>R01 AI090795</funding_grant_id><funding_grant_id>R56 AI084123</funding_grant_id><pubmed_authors>Barrett BS</pubmed_authors><pubmed_authors>Guo K</pubmed_authors><pubmed_authors>Hasenkrug KJ</pubmed_authors><pubmed_authors>Smith DS</pubmed_authors><pubmed_authors>Halemano K</pubmed_authors><pubmed_authors>Santiago ML</pubmed_authors><pubmed_authors>Heilman KJ</pubmed_authors><view_count>54</view_count></additional><is_claimable>false</is_claimable><name>Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.</name><description>Somatic hypermutation (SHM) is an integral process in the development of high-affinity antibodies that are important for recovery from viral infections and vaccine-induced protection. Ig SHM occurs predominantly in germinal centers (GC) via the enzymatic activity of activation-induced deaminase (AID). In contrast, the evolutionarily related apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3 (APOBEC3) proteins are known to restrict retroviruses, including HIV-1. We previously reported that mouse APOBEC3 encodes Recovery from Friend virus 3 (Rfv3), a classical resistance gene in mice that promotes the neutralizing antibody response against retrovirus infection. We now show that APOBEC3/Rfv3 complements AID in driving Ig SHM during retrovirus infection. Analysis of antibody sequences from retrovirus-specific hybridomas and GC B cells from infected mice revealed Ig heavy-chain V genes with significantly increased C-to-T and G-to-A transitions in wild-type as compared with APOBEC3-defective mice. The context of the mutations was consistent with APOBEC3 but not AID mutational activity. These findings help explain the role of APOBEC3/Rfv3 in promoting the neutralizing antibody responses essential for recovery from retroviral infection and highlight APOBEC3-mediated deamination as a previously unidentified mechanism for antibody diversification in vivo.</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 May</publication><modification>2020-11-19T11:58:16Z</modification><creation>2019-03-27T01:29:14Z</creation></dates><accession>S-EPMC4040588</accession><cross_references><pubmed>24821801</pubmed><doi>10.1073/pnas.1403361111</doi></cross_references></HashMap>